As of March 29, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.71. Arcutis Biotherapeutics Inc is up 4.59% from its previous closing price of $10.24. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.19 and $10.70. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ...See the company profile for Arcutis Biotherapeutics, Inc. (ARQT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ...Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Arcutis Biotherapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.914. Following the earnings report the stock price went up 9.91%. Which hedge fund is a major shareholder of Arcutis Biotherapeutics? Arcutis Biotherapeutics Inc. is based in Westlake Village, California. Stock Name, Country, Market Cap, PE Ratio. Amgen (AMGN), United States, $142.010B, 14.72.Mar 6, 2023 · Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45. Frank Watanabe. https://www.arcutis.com. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for …Review Arcutis Biotherapeutics Inc Ordinary Shares (ARQT:XNAS) stock's current information regarding return on assets, equity, invested capital, margins, and turnover over the last fiscal year.Frank Watanabe. https://www.arcutis.com. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic ...66.61%. Get the latest Arcutis Biotherapeutics Inc (ARQT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45.As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Aug 3, 2022 · In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and ... Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45.Volume, 2.35M. Market Value, $179.33M. Shares Outstanding, 94.38M. EPS (TTM), -$4.9489. P/E Ratio (TTM), N/A. Dividend Yield, N/A. Latest Dividend, N/A.These 6 analysts have an average price target of $34.83 versus the current price of Arcutis Biotherapeutics at $3.3701, implying upside. Below is a summary of how these 6 analysts rated Arcutis ...WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical …At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis …Arcutis Biotherapeutics Stock Forecast. All Analysts Top Analysts ARQT's stock price has decreased by -88.35% in the past year and price targets may not have had time to catch up. Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ARQT stock stock is $27.25, which predicts an increase …The Arcutis Biotherapeutics stock prediction for 2025 is currently $ 1.777134, assuming that Arcutis Biotherapeutics shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -12.46% increase in the ARQT stock price.Concurrent with the completion of the public offering, Arcutis sold to OrbiMed Advisors, LLC, an affiliate of one of the Company’s directors, 1,400,000 shares of its common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a price per share equal to the public offering price.Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall ...Currently, Arcutis Biotherapeutics has an average volume of 1.03M. Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.Concurrent with the completion of the public offering, Arcutis sold to OrbiMed Advisors, LLC, an affiliate of one of the Company’s directors, 1,400,000 shares of its common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a price per share equal to the public offering price.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.Arcutis Announces Pricing of $100 Million Public Offering. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningf... 4 weeks ago - GlobeNewsWire.Arcutis Biotherapeutics Inc (ARQT) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News Advertisement 3rd Party Ad. Not an offer or recommendation …Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6 CI Nov. 13: Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight RatingConcurrent with the completion of the public offering, Arcutis sold to OrbiMed Advisors, LLC, an affiliate of one of the Company’s directors, 1,400,000 shares of its common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a price per share equal to the public offering price.As of March 29, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.71. Arcutis Biotherapeutics Inc is up 4.59% from its previous closing price of $10.24. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.19 and $10.70. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ...Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...Arcutis Biotherapeutics Inc ARQT. Arcutis Biotherapeutics announced the pricing of a $100 million public offering of 32.5 million common shares at $2.50 per share. The company has a 52-week low of ...Latest Arcutis Biotherapeutics Inc (ARQT:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and ...The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The simple moving average for the last 20 days is …Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ...Jun 22, 2022 · One company hoping for such success is Arcutis Biotherapeutics (ARQT 4.08%). It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff ... Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.As of September 1, 2023, Arcutis Biotherapeutics Inc’s stock price is $8.96, which is up 4.92% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and ...Insider Monkey Transcripts. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Q4 2022 Earnings Call Transcript February 28, 2023. Operator: Ladies and gentlemen, thank you for standing by. And welcome ...0.50%. ¥2.18T. ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown.Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.There’s also Arcutis Biotherapeutics (NASDAQ:ARQT), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face FDA decision on Dec. 16.Jul 12, 2023 · Recent developments: Arcutis Biotherapeutics' stock rose 15% in early June after prescription data showed a 40% increase in Q1 for their psoriasis cream, Zoryve. Q1 2023 Earnings. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT). Biotechnology Research. Westlake Village, California 16,359 followers. Bioscience, applied to the skin.Arcutis Biotherapeutics - ARQT - Stock Price Today - Zacks Arcutis Biotherapeutics (ARQT) (Real Time Quote from BATS) $1.99 USD +0.03 (1.53%) Updated Nov 28, 2023 10:40 AM ET Add to...Arcutis Biotherapeutics Inc (ARQT) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News Advertisement 3rd Party Ad. Not an offer or recommendation …Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. Arcutis Biotherapeutics' shares are down 15% year to date. Read more to ...These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 01, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).Mar 6, 2023 · Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45. Mar 7, 2023 · As of March 07, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $13.69. Arcutis Biotherapeutics Inc is down 5.85% from its previous closing price of $14.54. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $14.43 and $15.47. Currently, there are 61.04 million shares of Arcutis ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) | 16,482 followers on LinkedIn. Bioscience, applied to the skin. | Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock and, in lieu of common stock to certain investors, pre-funded warrants.WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock and ...37.23M. MSFT. 378.61. +0.31%. 20.54M. View today's Arcutis Biotherapeutics Inc stock price and latest ARQT news and analysis. Create real-time notifications to follow any changes in the live stock ...Arcutis Biotherapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.914. Following the earnings report the stock price went up 9.91%. Which hedge fund is a major shareholder of Arcutis Biotherapeutics?Stock Quote & Chart. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High.Real time Arcutis Biotherapeutics (ARQT) stock price quote, stock graph, news & analysis. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. Morgan Stanley, Cowen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.At Arcutis, we fiercely value people—our patients, healthcare providers, team members, and our community at large. We aspire to be an upstanding global figure, with strong ethical standards embedded in our culture, and guiding our actions. We are a Great Place to Work ® -Certified company, a 2022 Fortune Best Workplaces in Biopharma™, and ...7. Arcutis Biotherapeutics. @ArcutisBio. ·. May 15. Fact: #atopicdermatitis (AD) is the most common type of eczema, affecting approximately 9.6 million children in the U.S. alone. A recent study uncovered how the burden of AD is perceived by children, adolescents, their caregivers, and dermatologists. Learn more below.Complete Arcutis Biotherapeutics Inc. stock information by Barron's. View real-time ARQT stock price and news, along with industry-best analysis.7. Arcutis Biotherapeutics. @ArcutisBio. ·. May 15. Fact: #atopicdermatitis (AD) is the most common type of eczema, affecting approximately 9.6 million children in the U.S. alone. A recent study uncovered how the burden of AD is perceived by children, adolescents, their caregivers, and dermatologists. Learn more below.The latest price target for Arcutis Biotherapeutics (NASDAQ: ARQT) was reported by Morgan Stanley on Monday, November 13, 2023. The analyst firm set a price ...ARQT is the ticker symbol for Arcutis Biotherapeutics, Inc., a company that develops immuno-dermatology products. The stock price, news, quote and history of ARQT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, research reports and more. Arcutis Biotherapeutics (ARQT) In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $57.00. The company’s ...Oct 20, 2023 · Arcutis is selling 32,500,000 shares of common stock and, in lieu of common stock to certain investors, pre-fu. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics ... The Arcutis Biotherapeutics Inc stock price fell by -0.529% on the last day (Wednesday, 22nd Nov 2023) from $1.89 to $1.88. During the last trading day the stock fluctuated 17.51% from a day low at $1.77 to a day high of $2.08. The price has fallen in 6 of the last 10 days and is down by -14.55% for this period.WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share ...1 thg 2, 2021 ... Stock of Arcutis Biotherapeutics, a Westlake Village-based company developing dermatological treatments, shot up more than 30% on Feb.About Arcutis Biotherapeutics Inc. Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical ...All of the shares of common stock and pre-funded warr. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) | 16,482 followers on LinkedIn. Bioscience, applied to the skin. | Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in ...0.50%. ¥2.18T. ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Do the numbers hold clues to what lies ahead for the stock? Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended ...WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock ...
View the latest Arcutis Biotherapeutics Inc. (ARQT) stock price, news, historical charts, analyst ratings and financial information from WSJ.. Chat gpt stock symbol
Nov 3, 2023 · ARQT stock had a significant performance on November 3, 2023. According to data from CNN Money, eight analysts have offered 12-month price forecasts for Arcutis Biotherapeutics Inc, with a median target of $33.00. The high estimate for the stock price is $50.00, while the low estimate is $4.00. The Arcutis Biotherapeutics Inc stock price fell by -0.529% on the last day (Wednesday, 22nd Nov 2023) from $1.89 to $1.88. During the last trading day the stock fluctuated 17.51% from a day low at $1.77 to a day high of $2.08. The price has fallen in 6 of the last 10 days and is down by -14.55% for this period.About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis …As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ...Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported, And Analysts Assigned A US$41.57 Price Target. (Simply Wall St.) Aug-10-23 08:16AM. Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia. (GlobeNewswire) Aug-09-23 09:23AM.Before we jump into Arcutis Biotherapeutics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet ...Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT). Biotechnology Research. Westlake Village, California 16,359 followers. Bioscience, applied to the skin.That’s why we’re here. Arcutis has a passion for doing and delivering better through innovation. But not just for the sake of innovating—innovation that delivers the results that matter most. The kind that simplifies complex disease management and solves the most persistent challenges of treating chronic inflammatory diseases of the skin.Arcutis Biotherapeutics Inc is down 6.97% from its previous closing price of $7.82. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $7.82 and $8.26. Currently, there are 61.43 million shares of Arcutis Biotherapeutics Inc stock available for purchase. Unfortunately, Arcutis Biotherapeutics Inc’s P/E ratio ...Aug 3, 2022 · WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock ... Arcutis Biotherapeutics (ARQT) Stock Price History Chart & Technical ...The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The simple moving average for the last 20 days is …August 8, 2023 at 4:02 PM · 11 min read. Arcutis Biotherapeutics, Inc. Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream ...ARCUTIS BIOTHERAPEUTICS INC Item 1(b) Address of issuer's principal executive offices: ----- 3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE CA 91361 Item 2. 2(a) Name of person filing: ... Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),Bioscience, applied to the skin. | Arcutis is addressing the innovation gap in medical #dermatology drug development. $ARQT #DermTwitter #Immunodermatology.Arcutis Biotherapeutics Inc. Watch list Set a price target alert Open Last Updated: Dec 1, 2023 1:02 p.m. EST Real time quote $ 1.9450 0.1050 5.71% Previous Close $1.8400 …Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The Investor Relations website contains information about Arcutis Biotherapeutics's business for stockholders, potential investors, and financial analysts. Dec 1, 2023 · See the latest Arcutis Biotherapeutics Inc Ordinary Shares stock price (ARQT:XNAS), related news, valuation, dividends and more to help you make your investing decisions. .